Wor

Lab Automation Networks Proliferating

Although it may still seem radically innovative in the context of many clinical laboratories, automated production in the manufacturing sector had been the norm for many years. In automobile assembly, for example, automated lines fabricate sub-assemblies and entire vehicles with only occasional human oversight. The result has been vastly improved products, far fewer defects, and significant p...

Immunoassay Systems - Your Laboratory Workhorse

Although new and innovative technology has enabled more and more laboratory testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests a...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced today the presentation of twoposters at the XIth Annual International Myeloma Workshop beingheld in Kos, Greece from June 25-28th, 2007. The meeting highlightsimportant advances made in the biology and treatment of multiplemyeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) geneexpression profil...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

PRINCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CytogenCorporation (NASDAQ: CYTO) reported updated data from a Phase 1dose escalation study evaluating QUADRAMET(R) (samarium Sm-153lexidronam injection) in combination with bortezomib (Velcade(R),Millennium Pharmaceuticals, Inc.) in patients with relapsedmultiple myeloma. Data from 33 patients were presented today in aposter titled, "Phase 1...

MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAPPharmaceuticals, Inc. today announced that it will present Phase 2data from its Unit Dose Budesonide (UDB) pediatric asthma therapyclinical program at the World Asthma Meeting at the Lutfi KirdarConvention and Exhibition Center in Istanbul, Turkey. The oral and poster presentation entitled, "Efficacy and safetyof a novel submi...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

-- More than 70 abstracts highlight VELCADE efficacy in broad rangeof patients and across continuum of care -- CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today announced that data forVELCADE, the market leading therapy with unsurpassed single-agentefficacy for patients with previously treated multiple myeloma(MM), will be featured at the upco...

Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation

LUND, Sweden, June 18, 2007-Active Biotech (OMX Nordic: ACTI)has presented pre-clinical data for the 57-57 project at the 8thWorld Congress on Inflammation (<a target="_blank" href="http://www.inflammation2007.dk/">www.inflammation2007.dk ) heldin Copenhagen June 16-20*. "The results strengthen the further clinical development of57-57 for the treatment of SLE and show the possib...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop

PRINCETON, N.J., June 14, 2007 /PRNewswire-FirstCall/ --Pharmasset, Inc. , a clinical-stage pharmaceutical companycommitted to discovering, developing and commercializing noveldrugs to treat viral infections, announced today that scientificdata presentations about Clevudine and Racivir were made during the16th International HIV Drug Resistance Workshop being held in St.Michael, Barbados...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

SAN MARINO, Calif., June 04, 2007 /PRNewswire/ -- (SEND2PRESSNEWSWIRE) -- Epeius Biotechnologies Corporation today announced thepublication of a historic landmark in medical oncology and adefinitive benchmark in the emerging field of cancer gene therapy.The first clinical report of its kind, Le Morte du Tumour --published in the June issue of the International Journal ofOncology, Vol.30,...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents and Small Vessel Size To BeIndependent Predictors of Need for Another Procedure MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX NewsNetwork/ -- An analysis of data from the Western Denmark HeartRegistry found that patients who received the CYPHER(R)Sirolimus-eluting Coronary...

World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester

Breakthrough in Research and Treatment of Rare but DevastatingCondition LONDON, June 1, 2007-Researchers at Queen Mary University Londonand the University of Leicester and have today (Friday June 1)announced a potential breakthrough in the treatment of a rare butdevastating medical condition that can affect children and youngpeople. In a world first, the clinicians and scien...

Abbott Announces Positive Nine-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Absorbable Stent Continues to Show Promise as Future-GenerationTechnology BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced positive results from ABSORB, the world's firstclinical trial evaluating the safety and performance of a fullybioabsorbable drug eluting stent platform for the treatment ofcoronary artery disease. Nine-month results from the first 30pati...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

Gentium's Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 23, 2007 -Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported thatits lead product, Defibrotide, will be the subject of a posterpresentation at the World Congress of Nephrology 2007 being held inRio de Janeiro, Brazil from April 21-25, 2007. On Monday, April 23, 2007, Cinara Echart, Ph.D., Manager ofBiological Research Laboratory...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem Cells Work Better

Stem Cells Isolated from Females Regenerate Skeletal Muscle MoreEfficiently than Male Cells PITTSBURGH, April 09, 2007 /PRNewswire/ -- Female stem cellsderived from muscle have a greater ability to regenerate skeletalmuscle tissue than male cells, according to a study at Children'sHospital of Pittsburgh of UPMC. The study, which is being published in the April 9 issue of theJournal...

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Ace Biosciences, Ace393, the World's First Commercial Vaccinefor Travellers' Diarrhoea Caused by Campylobacter SuccessfullyCompletes Phase I Clinical Trials Trial confirms good safety profile and strong immunogenicity ODENSE, Denmark, March 28, 2007 -ACE BioSciences A/S, theinfectious diseases company is pleased to announce the successfulcompletion of Phase I clinical t...

Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- A large patientregistry of "real world" uses for the CYPHER(R) Sirolimus-elutingCoronary Stent reported favorable safety and efficacy outcomes attwo-year follow-up, according to clinical investigators at the ofCardiology's 56th Annual Scientific Session (ACC.07). The MATRIX Registry is a prospective, single-arm study designedto evaluate t...

Abbott Announces Positive Six-Month Results From the World's First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent

Abbott's Bioabsorbable Stent Technology Holds Promise asFuture-Generation Treatment Option for Physicians Treating Patientswith Coronary Artery Disease ABBOTT PARK, Ill., March 24, 2007 /PRNewswire-FirstCall/ --Abbott today announced positive results from ABSORB, the world'sfirst clinical trial evaluating the overall safety and performanceof a fully bioabsorbable drug- eluting stent platf...

Laresse Dermal Filler Research Presented at Anti-Aging World Congress

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed,Inc. announced today that a review of the company's research onnovel, synthetic dermal fillers is being presented at theAnti-Aging Medical World Congress (AAMWC) in Monte Carlo March22-24, 2007. In 2006, FzioMed launched Laresse Dermal Filler, the firstultra-smooth, non-permanent, synthetic filler created from thecompany's...